HOURS
Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed
At Protheragen BioNucleics, we are committed to propelling innovation in oligonucleotide therapeutics. Our expertise in Oligonucleotide Drugs CRO, Oligonucleotide Modification Service, siRNA Modification Service, and siRNA Sugar Modification positions us at the forefront of RNA interference (RNAi) technology. We specialize in enhancing small interfering RNA (siRNA) through advanced modifications to improve their therapeutic potential.
The 2'-O-methyl (2'-OMe) modification is a pivotal technique in siRNA optimization. By substituting the ribose sugar's 2'-hydroxyl group with a methyl group, the modified siRNA exhibits increased nuclease resistance and reduced immunogenicity. This alteration enhances the molecule's stability in biological systems without compromising its ability to selectively silence target genes. The 2'-OMe modification is instrumental in extending siRNA half-life and improving pharmacokinetic properties, making it a cornerstone in the development of effective RNAi-based therapeutics.
We offer custom synthesis services for 2'-OMe modified siRNA, delivering high-purity oligonucleotides tailored to your specifications. Our synthesis platform accommodates various scales, from research quantities to large-scale production.
Our team provides siRNA design and optimization, incorporating 2'-OMe modifications strategically to enhance target specificity and reduce off-target effects. Utilizing advanced bioinformatics tools, we assist in selecting optimal sequences for maximum gene-silencing efficiency.
Ensuring the highest quality is paramount. We employ rigorous analytical techniques, including HPLC, mass spectrometry, and nuclease resistance assays, to validate the integrity and performance of our 2'-OMe modified siRNA products.
For projects advancing toward clinical development, we offer scale-up services compliant with good manufacturing practices (GMP). Our facilities are equipped to produce bulk quantities while maintaining consistent quality and reliability.
Effective delivery is key to siRNA efficacy. We offer formulation services, developing delivery systems such as lipid nanoparticles that enhance cellular uptake and bioavailability of 2'-OMe modified siRNA.
Q1: How does 2'-OMe modification improve siRNA performance?
The 2'-OMe modification increases siRNA stability by protecting against nuclease degradation. It reduces immunostimulatory responses and enhances specificity, minimizing off-target effects while maintaining gene-silencing activity.
Q2: Can Protheragen BioNucleics assist with the design of my siRNA sequences?
Yes, we offer expert design services, utilizing bioinformatics tools to optimize siRNA sequences with appropriate 2'-OMe modifications for your target gene.
Q3: What quality control measures are in place for modified siRNA products?
Our modified siRNA undergoes stringent quality control, including purity assessment by HPLC, molecular weight confirmation via mass spectrometry, and functional validation through nuclease resistance assays.
Our services and products are exclusively for authorized organizations in research, development, or manufacturing and are not intended for direct use by individuals or patients or as medical advice, diagnosis, or treatment.